<unk>  refers to a regimen consisting of rituximab, dexamethasone, high-dose cytarabine (Ara-C), and oxaliplatin (R-DHAOx) produces a strong long-term antitumor effect in previously treated patients with follicular non-Hodgkin's lymphoma.
R-DHAOx regimen
M-BACOD regimen
GVD regimen
DHAP regimen
RVD regimen
FMC-R regimen
FN-D regimen
CMF regimen